Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

Inclusion Criteria:

1. Written informed consent.

2. Males and females between the ages of 20 and 80 years.

3. Females of childbearing potential must have a negative pregnancy test, not be breastfeeding and established on a method of contraception that in the investigator'sopinion is acceptable. Females must agree to remain on their established method ofcontraception through their participation in the study and for 14 days following thelast dose of study drug.

4. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrolment) of myocardial infarction or significantcoronary artery disease with noninvasive or angiographic confirmation.

5. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormalexercise response limited by angina and/or electrocardiograph (ECG) changes.

6. Moderate angina pectoris (Class II or III, Grading of Angina Pectoris by the CanadianCardiovascular Society Classification System).

7. Patient whose symptom-limited Total Exercise Duration (TED) is between 3 to 7 minutesin Exercise Tolerance Test (ETT) on Standard Bruce Protocol, and symptom-limited TEDon two screen examinations (Day -7 and 0) in which the shorter is within 85% of thelonger .

8. Patient has been on one beta-blocker or on one calcium-channel blocker for at least 14days prior to dosing of study medication and can remain on this treatment throughoutthe study as background anti-anginal treatment. Short-acting nitroglycerin foron-demand use is allowed for all eligible patients.

9. Understand and be willing, able and likely to comply with all study procedures andrestrictions and comprehends the verbal rating scales and diary cards.

Exclusion Criteria:

1. With contraindication to, unable to, or with other co-morbidities that may prevent orinterfere with the ability to perform treadmill ETT (including, but not limited to:pulmonary hypertension, functionally limiting COPD (chronic obstructive pulmonarydisease), history of pulmonary tuberculosis, prior hospitalization for acuteexacerbation of chronic lung disease, home oxygen use, chronic oral steroid therapythat can limit exercise capacity, functionally limiting peripheral artery disease,etc.).

2. Presence of electrocardiographic or other abnormalities/factors that could interferewith exercise electrocardiograph interpretation or may lead to a false positive stresstest (e.g., pre-exercise horizontal or down-sloping ST segment depression in anystandard lead, cardiac glycoside therapy, Lown-Ganong-Levine Syndrome,Wolff-Parkinson-White syndrome (WPW), left bundle branch block, left ventricularhypertrophy with repolarization abnormality, implanted pacemaker, etc.).

3. Clinically significant arrhythmias or atrioventricular conduction block greater thanfirst degree, decompensated heart failure, atrial fibrillation, hypertrophiccardiomyopathy.

4. Acute coronary syndrome (acute myocardial infarction or unstable angina) in the prior 2 months or coronary revascularization within the prior 6 months or planned coronaryrevascularization during the study period.

5. Congenital cardiac defects, ongoing history of decompensated congestive heart failure,severe valvular disease, severe uncontrolled hypertension (seated systolic bloodpressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg), severe anemia,suspected or known dissecting aortic aneurysm, acute myocarditis or pericarditis,thrombophlebitis or pulmonary embolism.

6. History of bleeding diathesis, cerebral hemorrhage, or seizure disorders that requiredanticonvulsant medication.

7. Patients requiring the use of long-acting nitroglycerin, ranolazine, and/or multipleanti-anginal drugs.

8. Aspirin and/or statins started less than 14 days prior to the signing of informedconsent.

9. Pregnancy or lactation.

10. Clinical trials/experimental medication 1) Participation in any other clinical trialor receipt of an investigational drug within 30 days prior to the initial visit.

2. Previous participation in the studies of T89. 11. Substance abuse. Patients with arecent history (within the last 2 years) of alcoholism or known drug dependence.

12. Is a family member or relative of the study site staff. 13. Any other conditions that,in the opinion of the investigator, are likely to prevent compliance with the studyprotocol or pose a safety concern if the subject participates in the study.